Categories
Recommended Sites
- Actos Lawsuit
- Bing Search
- Conscious Evolution
- Free Health Insurance Quote
- Free Loan Quote
- Genistein Net
- Google Search
- HGH
- HGH Injections
- HGH Prescription
- HGH Side Effects
- HGH Therapy
- Hormone Therapy
- Injectable Testosterone
- Medical School Review
- NYC Bed Bugs Pest Control
- SEO Web Design
- Start Your Own Internet Services Company
- Testosterone
- Testosterone Replacement Therapy
- WholeSale Domain Names
Category Archives: FDA Stem Cell Trials
Small Biotech Companies Look to Benefit From Shift to "First to File" Patent System
NEW YORK, NY–(Marketwire -05/03/12)- Biotech stocks have continued to provide investors with strong gains in 2012. The iShares NASDAQ Biotechnology Index (IBB) is up nearly 20 percent year-to-date. The passage of the America Invents Act will look to benefit the Biotechnology Industry going forward “by enhancing patent quality and the efficiency, objectivity, predictability and transparency of the U.S. Continue reading
Posted in FDA Stem Cell Trials
Tagged a-few-minutes, a-patent-will, america-, america-invents, clinical-trials-, market-research, paragon, paragon-report, patents, president
Comments Off
Gene Ray, Founder of $2.6 Billion Titan Corp, Invests in Medistem's ERC Technology and Joins Advisory Board
SAN DIEGO, CA–(Marketwire -04/25/12)- Medistem Inc. (MEDS.PK – News) announced Dr. Gene Ray, founder of $2.6 Billion Titan Corp, has invested in and joined the Advisory Board for Medistem Inc Continue reading
Posted in FDA Stem Cell Trials
Tagged board, chairman, chemistry, department, development, entrepreneur, medistem, medistem-inc-, physics-, president, press, securities, space, unique, university
Comments Off
SynGen Inc. Receives $5 million Equity Investment from Bay City Capital, LLC
SACRAMENTO, Calif., April 18, 2012 /PRNewswire/ — SynGen Inc. (“SynGen” or the “Company”), a Regenerative Medicine device company focused on the development of next generation stem cell harvesting systems, announced today that it has completed a $5 million Series A preferred stock financing with Bay City Capital, LLC (BCC). Under the terms of the transaction, BCC will appoint two representatives to SynGen’s board of directors Continue reading
Posted in FDA Stem Cell Trials
Tagged a-top-tier, development, during-the-due, its-ease-of-use, make-the-syngen, our-accelerated, partner-at-bay, sterile-plastic, substantially, under-the-terms, venture-capital
Comments Off
New Data Demonstrates DIFICLIR™ May Offer Benefits for Cancer Patients, who are at High Risk of Clostridium Difficile …
STAINES, UK, March 31, 2012 /PRNewswire/ — Clostridium difficile infection (CDI), a potentially fatal disease, is one of the most common healthcare acquired infections inEurope[1] New data presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrate that in cancer patients with CDI, DIFICLIR(fidaxomicin) may offer significant benefits in terms of clinical cure*, recurrence[#] and sustained clinical cure[=].[2] The data presented were derived from two Phase III clinical trials. A post hoc analysis compared outcomes in patients who had a diagnosis of cancer with outcomes for patients who did not Continue reading
Posted in FDA Stem Cell Trials
Tagged a-longer-period, astellas-pharma, clinical-cure, clinical-trial, data-, effectiveness, europe, european, north, phase, post, president, professor, study, university
Comments Off
Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult …
SAN DIEGO, March 30, 2012 /PRNewswire/ — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR – News) announced the presentation of results from a post-hoc subgroup analysis of the company’s two large Phase 3 trials which demonstrated that cancer patients with Clostridium difficile-associated diarrhea (CDAD) had higher clinical cure rates, better sustained response and lower recurrence when treated with DIFICID (fidaxomicin) tablets compared to oral vancomycin. The data will be presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in London Continue reading
Posted in FDA Stem Cell Trials
Tagged a-10-day-course, analysis, department, houston, important, information, phase, president, safety, study, texas, time, university
Comments Off
Cardium Announces U.S. Market Introduction of Excellagen™
SAN DIEGO, March 30, 2012 /PRNewswire/ –Cardium Therapeutics (NYSE Amex: CXM) today announced market introduction of its Excellagen professional-use, syringe-based wound care product for the management of diabetic foot ulcers, pressure ulcers and other dermal wounds. (Photo: http://photos.prnewswire.com/prnh/20120330/LA79308) (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) Excellagen is a new, FDA-cleared highly-refined fibrillar collagen-based topical gel (2.6%) designed to support favorable wound care management. Continue reading
Posted in FDA Stem Cell Trials
Tagged a-logistics-and, advanced-wound, business, cardium, chairman, diabetic-foot, dna, excellagen, florida, management, medical, potential, south-korea, treatment, wound
Comments Off
Basketball’s influence on stem cell treatments in sports medicine
As the basketball frenzy that accompanies March Madness draws to the fever pitch of the Final Four, it brings to mind that basketball is a high contact sport. A quick peek at the NBA injured list reveals a catalog of breaks and tears that affect tendons, ligaments and bones. The pressure to improve performance and search for quick recoveries has led some celebrity athletes to seek out stem cell treatments overseas and in the U.S Continue reading
Posted in FDA Stem Cell Trials
Tagged a-drug-therapy, a-high-contact, a-sea-change, allan-houston, basketball, conversion, district-court, europe, money, press, sports, united, united-states, usa
Comments Off
Gentium Reports Fourth Quarter and Year End 2011 Financial Results
Defibrotide usage increased by 28% to EUR 16.89 million (US$ 21.91 million) Total product sales of EUR 21.73 million (US$ 28.19 million) Net income of EUR 2.71 million (US$ 3.52 million) Cash flow positive and stronger cash position VILLA GUARDIA (COMO), Italy, March 27, 2012 (GLOBE NEWSWIRE) — Gentium S.p.A. (Nasdaq:GENT – News) (the “Company”) today reported financial results for the quarter and year ended December 31, 2011. Continue reading
Posted in FDA Stem Cell Trials
Tagged a-more-timely, call, chairman, chief-executive, chief-financial, conference-, establishment, european, gentium, internet, islam, marketing
Comments Off
Seattle Genetics Announces Pivotal ADCETRIS™ (Brentuximab Vedotin) Hodgkin Lymphoma Study Published in Journal of …
BOTHELL, Wash.–(BUSINESS WIRE)– Seattle Genetics, Inc. (Nasdaq:SGEN – News) today announced that the Journal of Clinical Oncology (JCO) published results of the companys pivotal clinical trial of ADCETRIS (brentuximab vedotin) in Hodgkin lymphoma (HL) patients with relapsed or refractory disease following an autologous stem cell transplant (ASCT). Continue reading
Posted in FDA Stem Cell Trials
Tagged a-broad-array, a-linker-system, a-new-approach, bloodstream, director, hodgkin, journal, medical, pivotal, professor, university
Comments Off
Looking for Innovative Small-Cap Biotech Companies: George Zavoico
Like us on Facebook George Zavocio: I have a Ph.D. in physiology and I’ve worked for a number of pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Co Continue reading
Posted in FDA Stem Cell Trials
Tagged a-much-shorter, backs, experience-lies, fundamental, george-zavocio, healthcare, myers-squibb, oncology, pathogenesis, people-involved, small, wind
Comments Off